Could a single dose of MDMA supercharge PTSD therapy?

NCT ID NCT07288151

Recruiting now Symptom relief Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single dose of MDMA, given alongside two weeks of daily exposure therapy, can reduce PTSD symptoms more than therapy alone. About 95 adults with PTSD will take either MDMA or a placebo during one therapy session. Researchers will check symptom changes one month later using a standard interview.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MDMA (3,4-methylenedioxymethamphetamine)
What this could lead to: If successful, this could point toward a faster, more effective treatment for PTSD by combining a single dose of MDMA with intensive therapy.
What could go wrong: This is an early Phase 2 trial with only 95 participants, so results may not apply to everyone. MDMA can cause side effects like increased heart rate or anxiety, and the placebo group may show similar improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-TRAUMATIC STRESS DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Emory Brain Health Center
RECRUITING

Atlanta, Georgia, 30329, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.